FY2025 EPS Estimates for VYGR Increased by Cantor Fitzgerald

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities research analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for shares of Voyager Therapeutics in a research note issued on Wednesday, March 12th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings per share of ($2.03) for the year, up from their prior forecast of ($2.20). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share.

Several other brokerages have also recently commented on VYGR. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday. Citigroup began coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 price target for the company. Wells Fargo & Company set a $10.00 price target on shares of Voyager Therapeutics and gave the stock an “overweight” rating in a report on Wednesday. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Wedbush restated an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Voyager Therapeutics has a consensus rating of “Buy” and an average price target of $14.86.

Voyager Therapeutics Price Performance

Shares of VYGR opened at $3.90 on Friday. The firm’s 50 day moving average is $4.88 and its 200-day moving average is $5.85. The stock has a market capitalization of $213.04 million, a P/E ratio of 5.49 and a beta of 0.99. Voyager Therapeutics has a 12-month low of $3.56 and a 12-month high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The company had revenue of $4.39 million for the quarter, compared to analyst estimates of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the previous year, the business posted $1.25 EPS.

Institutional Trading of Voyager Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VYGR. Erste Asset Management GmbH bought a new stake in Voyager Therapeutics during the 3rd quarter worth about $6,192,000. Vestal Point Capital LP raised its holdings in Voyager Therapeutics by 151.0% during the 4th quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock worth $6,974,000 after buying an additional 740,000 shares during the period. Farallon Capital Management LLC raised its holdings in Voyager Therapeutics by 12.2% during the 4th quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock worth $14,576,000 after buying an additional 278,700 shares during the period. Dimensional Fund Advisors LP raised its holdings in Voyager Therapeutics by 24.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company’s stock worth $7,828,000 after buying an additional 275,571 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Voyager Therapeutics during the 4th quarter worth approximately $746,000. 48.03% of the stock is owned by institutional investors.

Insider Activity

In related news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now owns 112,328 shares in the company, valued at $634,653.20. This represents a 5.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders have sold 10,778 shares of company stock worth $58,548. Corporate insiders own 4.53% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.